# Effect of MD1003 in Amyotrophic Lateral Sclerosis

> **NCT03114215** · PHASE2 · COMPLETED · sponsor: **MedDay Pharmaceuticals SA** · enrollment: 30 (actual)

## Conditions studied

- ALS
- Amyotrophic Lateral Sclerosis
- Motor Neuron Disease

## Interventions

- **DRUG:** MD1003
- **DRUG:** Placebo oral capsule

## Key facts

- **NCT ID:** NCT03114215
- **Lead sponsor:** MedDay Pharmaceuticals SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-29
- **Primary completion:** 2017-06-12
- **Final completion:** 2017-12
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2019-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03114215

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03114215, "Effect of MD1003 in Amyotrophic Lateral Sclerosis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03114215. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*